Investigating how a specific receptor in the intestines can help relieve visceral pain.
Targeting visceral pain through intestinal neuropod cell GUCY2C signaling
['FUNDING_R01'] · THOMAS JEFFERSON UNIVERSITY · NIH-10931759
This study is looking at how a special receptor in the gut might help ease the pain and discomfort for people with constipation-related issues, like IBS-C and chronic constipation, by testing a new treatment that could improve their quality of life.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | THOMAS JEFFERSON UNIVERSITY (nih funded) |
| Locations | 1 site (PHILADELPHIA, UNITED STATES) |
| Trial ID | NIH-10931759 on ClinicalTrials.gov |
What this research studies
This research focuses on visceral hypersensitivity and pain associated with gut-brain interaction disorders, such as constipation-type irritable bowel syndrome (IBS-C) and chronic idiopathic constipation (CIC). It aims to understand the role of the guanylyl cyclase C (GUCY2C) receptor in alleviating visceral pain by activating specific signaling pathways. The study will explore how GUCY2C agonists can reduce pain and improve the quality of life for patients suffering from these conditions. By examining the mechanisms behind visceral pain relief, the research seeks to develop novel therapeutic options that go beyond current analgesics.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals suffering from visceral hypersensitivity related to conditions like IBS-C or CIC.
Not a fit: Patients with visceral pain not related to gut-brain interaction disorders may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly reduce visceral pain and improve the quality of life for patients with gut-brain interaction disorders.
How similar studies have performed: Previous research has shown promise in using GUCY2C agonists for pain relief, indicating a potential for success in this approach.
Where this research is happening
PHILADELPHIA, UNITED STATES
- THOMAS JEFFERSON UNIVERSITY — PHILADELPHIA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: WALDMAN, SCOTT A — THOMAS JEFFERSON UNIVERSITY
- Study coordinator: WALDMAN, SCOTT A
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.